Name |
Targets |
Phase |
Company |
pan-JAKs inhibitors |
|
|
|
Ruxolitinib / INCB-18424, INC-424 |
JAK1, JAK2, JAK3 |
2011 Filed |
Incyte |
Tasocitinib / tofacitinib, CP-690550 |
JAK1, JAK2, TYK2 |
2012 Filed |
Pfizer |
Baricitinib/ INCB-28050, LY-3009104 |
JAK1, JAK2 |
Phase III |
Incyte |
GLPG-0634 |
JAK1, JAK2 |
Phase II |
Galapagos |
CYT-387 |
JAK1, JAK2, TYK2 |
Phase II |
Cytopia |
AT-9283 |
JAK2, JAK3, BCR-ABL |
Phase II |
Astex |
INCB-16562 |
JAK1, JAK2 |
Preclinical |
Incyte |
Selective JAK2 inhibitors |
|
|
|
Pacritinib/ SB-1518 |
JAK2/FLT3 |
Phase III |
S*Bio |
Lestaurtinib / CEP-701 |
JAK2/PDGFR |
Phase III |
Caephalon |
AZD-1480 |
JAK2 |
Phase II |
AstraZeneca |
SAR-302503/ TG-101348 |
JAK2/RET |
Phase II |
Sanofi-Aventis |
LY-2784544 |
JAK2 |
Phase II |
Lilly |
BMS-911453 |
JAK2 |
Phase I |
Bristol-Myers Squibb |
NS-018 |
JAK2 |
Phase I |
Nippon Shinyaku |
TG02/ SB-1317 |
JAK2/CDK, FLT3 |
Phase I |
S*Bio |
SB-1578 |
JAK2/FLT3 |
Phase I |
S*Bio |
XL-019 |
JAK2 |
Phase I
(Termination) |
Exelixis |
AG-490 |
JAK2 |
Tools
compounds |
No company |
Selective JAK3 inhibitors |
|
|
|
R-348 |
JAK3 |
Phase I |
Rigel |
VX-509 |
JAK3 |
Phase I |
Vertex |
NC-1153 |
JAK3 |
Preclinical |
Texas Uni. |
|